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Abstract
Objectives To analyse the composition of the 
private pharmaceutical retail market in Malta on the basis 
of the originator or generic status of available medicines 
and to observe the change in prices of generics and 
originators over time.    
Method The prices of a sample (n=435) of medicines 
in Malta were analysed for an eight year period (2002 to 
2009). The variation in price in the generic and originator 
segments was calculated. Thirty-one active ingredients 
with generics available were identified and the Average 
Retail Price Per Unit (ARPPU) and the Lowest Retail Price 
Per Unit (LRPPU) were calculated. The average discount 
from the originator price was calculated, per compound 
and also by drug class.                                                                                              
Key Findings The sample population contained 
17.2% generic products. The mean drop in the ARPPU was 
of 10.87% and for the LRPPU of 21.42% for the LRPU.  The 
average discount was 14.59% in 2002 and 37.19% in 2009.       
       
Conclusion The number of generic medicines 
in Malta has increased in the last eight years, with a 
consequent decrease in the lowest prices available for the 
set of medicinal compounds.
Keywords Generic medicines, price discount and 
originator products
Introduction
The high cost of medicines for sale at the neighbourhood 
pharmacy is cause for concern both locally1 and 
elsewhere.2 Public and private consumers are facing 
budgetary constraints in dealing with a growing range of 
medicinal products and an increasing number of patients,3 
especially in view of the fact that life expectancy is on 
the rise and with it the incidence of non-communicable 
disease.4
Generic medicines are seen as the key to ease the financial 
pressures within healthcare systems worldwide.5, 6, 7 The 
entry of a generic product onto a market usually has a 
two-fold downward effect on prices. Firstly, the generic 
is cheaper, because it costs less to produce, and secondly 
because it needs to have a competitive edge to impact the 
end-consumer. 8
Generics are essential from an economic viewpoint, as 
they introduce competition to a situation where patent 
holders have held a manufacturing monopoly for the term 
of the patent period. 9, 10 This period of monopoly leads 
to a high price being exacted for a unique product, in this 
case for innovative drug molecules.
The local market had not been analysed with respect to its 
relative composition of originator or generic medicines. No 
specific information was available regarding the prices of 
generic medicines in relation to their respective originator 
products.  The aims of the study were to analyse the 
composition of the private pharmaceutical retail market 
in Malta on the basis of the originator or generic status of 
available medicines and to observe the change in prices of 
generics and originators over time.
Method
A sample (n=435) of medicines was drawn from the 3100 
medicines which had a Marketing Authorisation according 
to the Malta Medicines Authority in October 2009.  The 
sample was drawn by selecting in descending order on 
the basis of highest volume of sales in three community 
pharmacies over an eight year period (2002-2009).  Fields 
included in the data set were the originator or generic 
status, prescription-only status (POM) or non-prescription 
(OTC) status and drug class. The latter classification was 
based on the one used by the British National Formulary 
(BNF). 
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Medicine prices were compiled from computerized EPOS 
data generated by a live system that contained the prices 
as recommended by the competent authorities. A set of 
originator drugs which had generic equivalents by the 
end of 2009 was selected from the sample. This data set 
consisted of thirty-one active ingredients. The Average 
Retail Price Per Unit (ARPPU) and the Lowest Retail Price 
Per Unit (LRPPU) for each active ingredient was calculated 
for 2002 and 2009.  The unit measurements in the ARPPU 
and LRPPU were calculated by dividing the prices obtained 
for the medicines by the pack size so as to obtain a 
comparable variable.
The average percentage discount from the originator 
price to the generic version was calculated for the thirty-
one active ingredients for the years 2002 and 2009, by 
tabulating the retail prices of originator and generic 
versions for the two years in question, and including tags 
for OTC/POM and drug class identifiers.  
Results          
The sample population contained 17.2% generic products.  
The mean increase in price for the whole sample was 
17.86%. The mean for the originator segment showed 
an increase of 18.22%, with that for the generic segment 
rising by 16.2%. When the prices were composited into 
a retail medicine index the increases were 11.01%, and 
11.05% and 10.68% respectively.
Of the 31 active ingredients considered in the second 
part of the study, 16 had no generic equivalent in 2002, 
as opposed to the fact that all had at least one in 2009.  
This is reflected in the mean discount from the originator 
price for the data set, which rose from 14.59% to 37.19%. 
The greatest percentage discount observed is that for the 
Retail Price Per Unit (RPPU) of omeprazole 20mg capsules, 
and the lowest for paroxetine 20mg tabs, where the 
price of the originator and generic brands have simply 
decreased side by side to almost identical levels (Figure 1).
The class exhibiting the greatest discount from the 
originator price was the gastro-intestinal (GIT) segment, 
with cardiovascular (CVS) medicines in second place. The 
CVS segment was, however, the most populated, with 13 
active ingredients as opposed to the second most popular, 
the anti-infective drugs (AB & OTH), with 6, out of a total of 
31 compounds (Figure 2).
Twenty-seven out of the group of compounds were POM 
medicines, with the average discount from the originator 
price to the lowest available rising to 38.41% from 30.88% 
in this case. No appreciable change was noted for OTC 
medicines (27.28% to 28.92%).
Discussion
The fact that the prices of medicines exhibited an increase 
over an eight year period is not anomalous. The prices 
of both originator and generic drugs showed an upward 
movement. This statement is somewhat mitigated by the 
fact that upon further scrutiny it transpires that the prices 
for the OTC segment (16.22%) increased more than the 
POM one (7.21%). A greater increase in OTC medicine prices 
might be explained by the fact that this segment is highly 
incentivised and results in the cost being passed on to the 
consumer.  The mean drop in the lowest price available for 
retail for the thirty-one active ingredients studied, 21.42%, 
is not substantial when considered as a single variable. 
Studies in the EU have shown that the price of a generic 
medicine drops to 80% that of the originator within 
the first year of launch, leading to savings being passed 
on to the consumer11. Savings are even greater in the 
United States where prices drop by 80% after one year.12 
The intense generic competition in the North American 
market instigates greater investment in the research and 
development of innovative compounds. Expenditure 
on R&D exhibited an increase after the publication of 
the Hatch-Waxman Act, legislation which facilitated the 
introduction of generic medicines in the United States.13
Although the local market has no originator branded 
manufacturers, all the major companies maintain strong 
representation, and the presence of generics is vital on 
two counts. Firstly, to ensure that monopolistic situations 
are not maintained, thus providing the stimulus to 
bring newer protected products to the local market and 
secondly, to provide competition on the basis of price and 
exert downward pressure.13
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The great majority of the medicines in the originator/
generic pairings are POM medications. Almost half of the 
pairings surveyed belonged to the cardiovascular group 
of drugs. The use of this class of drugs increases with 
age, as the cardiovascular system begins to experience 
problems of decreasing cardiac output and increased 
peripheral resistance.14 It can be deduced that generic 
drug manufacturers are following the lead of the branded 
originator companies and launching products targeted 
at the elderly, so as to take advantage of this increasing 
demographic shift.
Conclusion
The entry of generic products on the market does not have 
a significant impact on retail prices. Further investigation 
into the pricing strategy of generic products is required. 
Measures could be introduced to ensure that generic 
medicines enter the market at a discount to the originator 
product. It might be proposed that  the granting of a 
Marketing Authorisation for a generic version of a product 
that is already present on the market under another brand, 
would only be undertaken if the Recommended Retail 
Price would be at a fixed percentage cheaper than the 
latest mean price for the Defined Daily Dose.
Without an effective education campaign, the further 
penetration of generic medicines, will be inevitably 
delayed.15, 16 This will prevent immediate savings in 
spending on pharmaceuticals and thus reduce accessibility 
to medical care. It is incumbent to enable a balance to 
be struck between the needs of innovation and branded 
manufacturers and those of lower-priced, high volume and 
accessible generic products.
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“The great majority 
of the medicines 
in the originator/
generic pairings 
are prescription 
-only medications. 
Almost half of the 
pairings surveyed 
belonged to the 
cardiovascular 
group of drugs”
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Figure 1 - The percentage discount for the RPPU from the originator product for each active 
ingredient for 2002 and 2009
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Figure 2 - The percentage discount by drug class in 2002 and 2009
“The entry of generic products 
on the market does not have 
a significant impact on retail 
prices. Further investigation 
into the pricing strategy of 
generic products is required”
